JOIMEMVI Trademark
Trademark Overview
On Tuesday, March 28, 2023, a trademark application was filed for JOIMEMVI with the United States Patent and Trademark Office. The USPTO has given the JOIMEMVI trademark a serial number of 97860538. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, April 1, 2025. This trademark is owned by Athira Pharma, Inc.. The JOIMEMVI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Scleros...
General Information
| Serial Number | 97860538 |
| Word Mark | JOIMEMVI |
| Filing Date | Tuesday, March 28, 2023 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Tuesday, April 1, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 4, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Athira Pharma, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Bothell, WA 98011 |
Trademark Events
| Event Date | Event Description |
| Thursday, December 21, 2023 | ASSIGNED TO EXAMINER |
| Friday, March 31, 2023 | NEW APPLICATION ENTERED |
| Tuesday, April 4, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, January 10, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 10, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 10, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, July 3, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, July 3, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, July 3, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, October 25, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, December 4, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, December 4, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, December 4, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, January 26, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, January 26, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, July 16, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, April 1, 2025 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, April 1, 2025 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
